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Abstract
Background: ‘Living with IPF and an exploration of Esbriet® – a new treatment’ was an exploratory, qualitative,
real-world survey of European patients with idiopathic pulmonary fibrosis (IPF) who were receiving treatment with
pirfenidone prior to its commercial availability. The aim of the survey was to probe the impact of IPF on patients’
quality of life; the role of healthcare professionals and caregivers; the information needs of both patients and their
caregivers; and patients’ perceptions of pirfenidone as a new treatment option for IPF.
Methods: Patients from the UK, Germany and Italy, with a diagnosis of IPF (duration >3 months), who were
being treated with pirfenidone, were recruited from patient support groups, specialist centres and advocacy
groups. Semi-structured, qualitative, in-depth patient interviews of 1-h duration were conducted by an
independent researcher. Patients were initially asked about their experiences of living with IPF and then
prompted to describe their experiences of taking pirfenidone. Techniques utilised included: the bubble-speech
technique; the icon cards projective exercise; and the free association exercise. All interviews were transcribed
and analysed by an independent researcher.
Results: Forty-five patients (71 % male) were interviewed (mean age 68.5 years; mean time since diagnosis
3.5 years); 87 % of patients reported that diagnosis took >1 year. Patients reported that IPF had a
significant physical and emotional impact on their quality of life. The beneficial role played by caregivers
and interstitial lung disease specialist nurses (where available) was specifically highlighted. Although most
patients were keen for information on IPF, this was often of poor quality, out of date, or in English only.
Patients’ perceptions of pirfenidone were largely positive and associated with ‘hope’ but were also
influenced by the level of side effects experienced.
Conclusions: This survey highlights the impact of IPF on patients’ lives, and the need to adequately support
both patients and their caregivers. These findings demonstrate the value of seeking patients’ perspectives of a
chronic disease such as IPF and how this information can be used to guide improvements in care, to best
support the needs of patients with this devastating condition.
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Background
Idiopathic pulmonary fibrosis (IPF) is a chronic, progres-
sive and irreversible interstitial lung disease (ILD) with a
poor prognosis (2–5 years) [1–5]. IPF is predominant in
men aged >50 years and, although idiopathic, risk factors
may include gastroesophageal reflux, smoking and envir-
onmental or occupational exposures [1, 3].
IPF imposes limitations on many daily activities, ne-
cessitating a change in lifestyle. In addition to impacts
on physical and social function, patients may also experi-
ence increased anxiety, depression and a reduced quality
of life [6–8]. Increased sleep disruption and a poorer
quality of sleep contributes to fatigue, further impacting
the emotional and physical well-being of patients [9–11].
The impact of IPF affects not only patients but also
caregivers, family and other members of patients’
support networks, all of whom have a role to play in
helping to manage the burden of the disease [12, 13].
Until recently, the standard of care for patients with
IPF was limited to oxygen therapy, pulmonary rehabilita-
tion, palliative care and, in a small minority of patients,
lung transplantation [1, 14]. Pirfenidone (Esbriet®), an
antifibrotic drug with anti-inflammatory properties, was
approved by the European Medicines Agency (EMA) in
2011 for the treatment of adult patients with IPF based
on the favourable benefit-risk profile observed in Phase
III clinical trials [15, 16]. The US Food and Drug
Administration simultaneously approved pirfenidone
and a tyrosine kinase inhibitor, nintedanib, for the treat-
ment of patients with IPF in the USA, in October 2014
[17–20]; the EMA subsequently approved nintedanib in
January 2015 [21].
Here, we report findings from ‘Living with IPF and an
exploration of Esbriet® – a new treatment’, an explora-
tory, qualitative, real-world survey of European patients
with IPF who were receiving treatment with pirfenidone
prior to its commercial availability. The aims of this
survey were to: explore patients’ experiences of living
with IPF and how this impacted on their quality of life;
determine the availability and impact of support systems,
specifically that of healthcare professionals (HCPs) and
caregivers; establish the information needs of both pa-
tients with IPF and their caregivers; and explore patients’
perceptions of pirfenidone as a new treatment option.
Methods
Design and patients
Patients were invited to enrol through patient support
groups (UK), specialist centres (Italy) or an advocacy
group (Germany). Eligible patients had a multidiscip-
linary team-confirmed diagnosis of IPF with disease
duration >3 months. All patients were being treated
with pirfenidone as part of a Named Patient Program
(NPP) under the supervision of an ILD physician.
Patients completed a screening questionnaire to verify
their IPF diagnosis and that they were receiving treat-
ment with pirfenidone. Forced vital capacity was not
recorded as part of the questionnaire and, while the
NPP was in principle limited to patients with mild-to-
moderate disease, the decision to ultimately treat each
patient was the responsibility of each participating
physician, and, therefore, the inclusion of patients with
more advanced disease cannot be excluded. All patients
provided consent for their participation in the survey
and for the future publication of anonymised findings
from the survey.
Interviews
Semi-structured, qualitative, in-depth patient interviews
of 1-h duration were conducted by an independent
researcher at a neutral venue or in the patient’s own
home, according to preference. Interviews were con-
ducted 1:1, although caregivers could be present at the
patient’s request. Interviews were audio- and video-
recorded (patients were asked not to identify themselves
on tape). Patients’ experiences of living with IPF, as
reported in this manuscript, were discussed initially;
patients were then asked about their experiences of
taking pirfenidone. The full interview discussion guide is
provided (see Additional file 1). The interviews were
designed to encourage frank, open discussion and to
probe patients’ unmet needs and the emotional and
rational elements driving their choices and behaviours.
Techniques utilised in the interviews included: the
bubble-speech technique, to probe patients’ expectations
of their HCP and their level of satisfaction with the
relationship; and the icon cards projective exercise
and free association exercise to assess possible new
formulations of pirfenidone.
Analysis
All interviews were transcribed verbatim and, where
necessary, translated into Italian; transcriptions were
anonymised in accordance with local data protection
laws and European Pharmaceutical Market Research
Association Guidelines. Interview transcriptions were
analysed by an independent researcher, and common
themes and challenges were extracted and summarised.
Disease awareness was determined by motivational and
qualitative factors concerning the disease and knowledge
of specific terminology. Side effects were reported as per
the respondent’s spontaneous answers and were not
analysed by a physician.
Results
Patients
Forty-five patients (71 % male) from three European
countries (UK, Germany and Italy) were interviewed
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between 24 September and 19 October, 2012. All
patients were invited to participate and approximately
80 % of the interviews were conducted with the
caregiver present. Mean age was 68.5 years and mean
time since diagnosis was 3.5 years at the time of
interview. Patients reported that diagnosis frequently
involved visits to several different HCPs, and 87 % of
patients reported that diagnosis took more than 1 year.
Approximately 90 % of patients were receiving oxygen
therapy: 55 % used oxygen as needed, for a few hours of
the day, while 35 % used continual oxygen therapy.
Impact of IPF on quality of life
Approximately half of the patients reported that IPF had
a significant negative impact on their quality of life. The
most frequently reported physical symptom of IPF was
fatigue (82 % of patients). Other physical symptoms
reported by >50 % of patients included loss of appetite
(typically in response to feelings of nausea), difficulty in
lifting objects (eg, grocery bags), and continuous phlegm
and coughing throughout the day.
“Even the simplest things are difficult for me”
(Patient – Italy)
Patients reported that the physical impact of IPF often
took an emotional toll, leaving them feeling depressed
and often without the emotional strength to fight disease
progression. The primary emotional concern reported by
patients was fear of the disease progression and its
impact on their future (72 % of patients). In addition,
36 % of patients reported feeling frustrated and angry,
due to a lack of self-acceptance of their disease and
other people’s poor knowledge of IPF. Patients also re-
ported feeling isolated (18 %), causing them to withdraw
from social relationships.
“I feel really sad; before I was a very cheerful person”
(Patient – Germany)
Patients reported that IPF also impacted on family life.
Some patients perceived themselves to be a burden and
felt reliant on their family, leading to additional frustra-
tion for the patient. Most female patients (90 %)
reported a loss of identity as the main family support
figure, and some of the male patients (15 %) reported a
detrimental impact of IPF on their sex lives, both
physically and emotionally. No other gender differences
were identified.
“I don’t know what type of life I can offer my wife, I
don’t feel like a man anymore, because of me I am
forcing restrictions on myself and other people”
(Patient – Italy)
“My family checks everything I do, I don’t feel free”
(Patient - UK)
The initiation of oxygen treatment marked an import-
ant stage in disease progression for all patients, due to
the perceived limitations it placed on their freedom.
Oxygen therapy was associated with less hope for the
future and more feelings of shame as their condition
became externally visible to others.
“I’m always hooked up to the oxygen, I have a range of
movement of 10 m” (Patient – Italy)
The role of HCPs and caregivers
In the UK, 90 % of patients reported that an ILD
specialist nurse was their main medical contact for
IPF healthcare. Nurses provided information on IPF,
patient support organisations and lifestyle advice, as
well as helping patients to access medication and
manage side effects.
“She [the nurse] is everything for me, she is a shoulder
to cry on, she answers any question I ask her, I hope
she never leaves!” (Patient – UK)
In Germany, patients reported that physicians were
their main contact, particularly concerning treatment
efficacy and side effects, whereas nurses played a more
marginal role in their care. In Italy, patients perceived
IPF as a rare condition requiring specialist knowledge;
they reported that nurses were not involved in their
care and that they generally interacted exclusively
with their physician.
“I am one of many patients; it is not easy to build a
relationship” (Patient –Germany)
“The doctor is my reference; he is the person I call,
definitely not the nurse who does not know much”
(Patient – Italy)
Most patients reported feeling that they lacked the
psychological support necessary to face their IPF-related
difficulties, with only one-fifth of patients having
received professional psychological support.
“The doctors helped me, but I have never received
any psychological support, I really need it”
(Patient – Germany)
More than half of the patients felt they needed a
caregiver in their household. Patients reported several
important roles that were fulfilled by caregivers, includ-
ing reminding patients to take medications, accompany-
ing patients to medical appointments and researching
information on IPF. Many caregivers present during the
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interviews demonstrated a greater knowledge of IPF
than the patient.
Information needs of patients and their caregivers
The level of disease awareness varied widely amongst
patients, but approximately one-third of patients felt
inadequately aware of or informed about IPF. Patients in
the UK and Germany largely understood the severity of
their IPF and their prognosis, as well as the available
treatments, whereas patients in Italy generally reported
being less well-informed about IPF and mostly relied
only on information provided by their physician.
“No idea about the name of this disease, I call it lung
infection” (Patient –Italy)
Most patients (74 %) reported searching for information
about IPF. However, many patients described issues with
what they found, including poor-quality and out-of-date
information, which was only available in English.
“It’s imperative to have information about this disease”
(Patient – Germany)
Patients in the UK and Germany preferred to receive
information about IPF online – most frequently via the
Pulmonary Fibrosis Foundation, British Lung Foundation
(BLF) and LungenFibrose websites – whereas Italian
patients preferred printed materials. The main areas
of patient interest included information on IPF, the
use of pirfenidone, and updates on new research and
therapy (Table 1). Emerging needs spontaneously reported
by patients concerned a lack of expert advice relating to
lifestyle (51 %), diet (38 %), oxygen treatment (38 %) and
physical exercise (18 %). Many patients reported that they
would like to receive practical information about lifestyle
changes that would help them manage their disease.
Patients also expressed an interest in knowing how many
other people in their area were affected by IPF and wanted
the general public to be better informed about the disease.
Caregivers reported feeling inadequately prepared for
the caregiving role. Caregivers stressed a need to receive
adequate psychological support to accept the disease
and better relate to the patient; a need for strategies to
manage the everyday life of a patient with IPF; and a
need for more background information on IPF.
“It is difficult for us to help them, we would like to
have more information about what we should do at
home” (Caregiver – UK)
Patients’ perceptions of pirfenidone
Patients’ perceptions of pirfenidone were largely positive,
scoring 7.4 on a scale of 0 (not satisfied) to 10 (very
satisfied). Satisfaction was influenced by the level of side
effects experienced by patients, with an average satisfac-
tion score of 6.1 (n = 25) for patients with side effects
and 8.3 (n = 20) for patients with no side effects. Side
effects, including nausea and photosensitivity, were re-
ported to have a negative psychological impact on
patients who perceived little awareness of their treat-
ment working. Patients with side effects also reported a
general deterioration in their quality of life, which they
perceived to be related to pirfenidone. Furthermore, if a
patient was experiencing side effects, they often attrib-
uted all of these effects to pirfenidone, even if any
correlation between the two was unconfirmed.
‘I have so many problems, such as nausea, itchy legs
and backache’ (Patient – Germany)
Patients without side effects reported feeling that their
condition had stabilised with the use of pirfenidone,
which in turn gave them a sense of hope and the feeling
they were being taken care of by HCPs. Patients
reported feeling reassured when HCPs confirmed their
disease had stabilised (according to clinical parameters),
which gave them greater confidence for the future.
“I feel I’m taking something that can really halt this
disease and make me live longer” (Patient – Germany)
“Ever since I started taking pirfenidone, I feel more
protected” (Patient – Italy)
Discussion and conclusions
IPF is a devastating disorder and the findings of this
qualitative survey of UK, German and Italian patients
with IPF add to the existing body of knowledge regarding
the substantial impact IPF has on the lives of patients and
their caregivers [6–11]. In agreement with recent litera-
ture [12, 22], these findings also identify the need to more
adequately support patients with IPF in terms of disease
awareness, lifestyle management, psychological support
Table 1 Patients with IPF indicated clear needs for information in three areas
IPF Pirfenidone Updates on new research and therapies
Greater knowledge about IPF,
the causes of the disease and
the number of people affected
More data regarding the efficacy
and tolerability of pirfenidone,
including how to practically
manage tolerability issues
Information on the new drugs
that are being studied for IPF,
including results from clinical trials
IPF idiopathic pulmonary fibrosis
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and management of medication side effects, as well as
emphasising the important role played by the HCP in
having primary contact with the patient and their family.
Approximately one-third of patients in the survey were
identified as being unaware of and/or uninformed about
IPF, and most patients wanted a better understanding of
the disease. However, sources of information on IPF
were frequently of poor quality, out of date or not avail-
able in the patients’ native language. In the UK and
Germany, patients predominantly used online sources
when looking for further information about their condi-
tion, while Italian patients reported a preference for
printed materials; however, it was unclear whether this
was actually due to preference or to a lack of web-based
IPF information in Italian. In general, however, when
diagnosed with a chronic disease such as IPF, many
patients now turn to online sources of health informa-
tion as this allows them a degree of autonomy, and the
ability to examine and digest information at their leisure
[23]. The findings of this study support the need for
good-quality, freely available, online information on IPF
in multiple languages, to support patients in learning
more about the practical management of their disease. It
is also interesting to note that many patients expressed a
desire for better understanding of IPF among the general
public. The recent US EXPLORE survey found that
patients with IPF often felt isolated, embarrassed and
stigmatised [24], and patients with other chronic respira-
tory diseases, such as chronic obstructive pulmonary
disease, often also report feeling stigmatised [25].
The findings of this survey also emphasise the import-
ant role played by the HCP who is the primary contact
for a patient, whether they are a physician or a specialist
nurse. In the UK, specialist nurses were reported to play
an important role in supporting patients with many
aspects of disease management and patients clearly felt
this was beneficial. However, the UK is quite unique in
having advanced ILD specialist nurses who are able to
play a significant role in helping patients understand the
disease and coordinate their care [22]. In a recent report
by the BLF, 50 % of English healthcare trusts reported
allocating an ILD specialist nurse within 6 months of a
patient’s diagnosis [22]. Furthermore, UK clinical guide-
lines state that all patients with IPF should have an ILD
specialist nurse allocated to them and that any centre
that wants specialist status must employ a specialist ILD
nurse [26]. UK clinical guidelines also recommend that
the ILD specialist nurse should provide accurate and
clear information to patients and their families, regard-
ing diagnosis and management of IPF, and support the
patient at all stages of the care pathway to facilitate
transitions in care and advise on symptom management
[26, 27]. In Germany and Italy, nurses were less in-
volved in patient care. Specialist nurses for IPF care
may warrant consideration by German and Italian
healthcare authorities due to their ability to provide a
holistic programme of care.
Caregivers were present in 80 % of the interviews
conducted for this survey and provided a useful source
of information. However, it should be acknowledged that
the presence of caregivers during the interview may have
inhibited responses from some patients. Nevertheless,
the findings of this survey support the difficulties faced
by caregivers in looking after patients with IPF and are
in agreement with the literature. The caregivers of pa-
tients with IPF have reported hardships throughout the
course of a loved one’s disease, including emotional dev-
astation at the initial diagnosis and difficulties living with
a loved one because of their limitations [28, 29]. Further-
more, providing additional support to caregivers of pa-
tients with IPF has been demonstrated to provide some
positive benefits. For example, caregivers who attended a
6-week nurse-led group intervention programme on IPF
management, alongside their loved ones with IPF, re-
ported significantly lower stress levels post-intervention
compared with those who did not attend the interven-
tion programme [29].
Pirfenidone was the first medication approved for the
treatment of European patients with IPF, and the posi-
tive feedback reported in this survey suggests it provides
hope and reassurance to patients. However, the findings
of this survey also highlight the need for guidance on
how to identify and mitigate the side effects experienced
by some patients during treatment with pirfenidone,
such as the nausea and loss of appetite reported as
symptoms of IPF in this study, which may have been
related to pirfenidone therapy [16, 17] rather than to IPF
itself. It should be noted that this survey was conducted
in 2012, prior to the launch of pirfenidone in some
European countries (including the UK). At this time,
HCPs would have been less familiar with pirfenidone
and its side-effect profile than they are at present.
Recent reports from real-world studies suggest that the
tolerability issues with pirfenidone can be well managed,
with no new safety signals identified versus the clinical
trial programme [16, 17, 30, 31]. However, there remains
a need to provide patients with lifestyle guidance
when they are taking pirfenidone to minimise the risk
of treatment side effects. Some strategies that have
proved successful include using sun protection to
avoid photosensitive skin reactions and taking pirfeni-
done during or after a meal to alleviate effects on
gastric motility [32].
While this survey reports the impact IPF has on
patients’ lives and supports the need to address the
unmet needs of patients’ and their caregivers, several
limitations must be addressed. The survey was not
designed to exclusively evaluate patients’ experiences of
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IPF. No formal measure of quality of life was imple-
mented and patients were not randomly selected for
participation in the survey. Furthermore, the sample size
was small, although this is typical of other surveys that
have been conducted in patients with IPF [2, 6, 11].
Developments in IPF management and disease awareness
As a result of surveys such as this one, many aspects of
care for patients with IPF in Europe have changed since
2012. In 2013, the patient support initiative ‘IPF Care’
was established in eight European countries, to provide
help and education for patients treated with pirfenidone
through frequent discussions with ILD specialist nurses.
The benefits of the programme are already receiving
recognition, such as in the UK where 66 % of patients
who reported an adverse event during the ‘IPF Care’
programme remained on maintenance therapy [13], and
in Austria, where 96 % of patients who started pirfeni-
done with the support of ‘IPF Care’ remained on
treatment for ≥3 months compared with only 64 % of
patients who were not enrolled in the programme [13].
The success of ‘IPF Care’ demonstrates the value that
patient support programmes can offer as a tool for
complementing and enhancing the support provided by
healthcare systems, and as a forum within which to
discuss patients’ worries. Other initiatives include IPF
World Week, established in 2012, to raise awareness of
the disease through its ‘Blowing Bubbles’ campaign in
several European countries [33], and the European IPF
Patient Charter, established to support equal access to
IPF treatment and care standards in Europe [34].
In the UK specifically, there have been many advances
in IPF, including the launch of two patient advocacy
groups (Pulmonary Fibrosis Trust in 2011 [35] and
Action for Pulmonary Fibrosis in 2013 [36]), which
provide information and support to patients, and the
launch of a clinical pathway for IPF in early 2015 [37].
Furthermore, the BLF has supported the development of
many projects, including an IPF Patient Charter (supported
by multidisciplinary IPF experts, patients and caregivers)
[38], a survey evaluating patients' experiences in England
[22] and numerous sources of patient information. The BLF
is also contemplating the development testing the feasability
of a personal organiser for patients with IPF in the UK.
In Italy, general awareness of IPF is slowly improving;
for example, there are several patient associations,
including RespiRARE in Sicily, dedicated to rare lung
diseases [39] and Ama Fuori dal Buio, which is very
active in supporting patients and providing them with
disease information [40]. The Observatory for Rare
Disease conducted a successful social-media campaign
inviting people to post pictures or videos of them trying
not to breathe, to raise awareness of IPF [41], and in 2013,
a patient- and caregiver-specific website was launched
with disease information in Italian [42]. Italian clinical
guidelines for IPF were also recently published [43]. In
Germany, the patient association Lungenfibrose e.V is also
very active in supporting patients and providing disease
information [44], and clinical guidelines for IPF were
launched in 2013 [45].
Future directions in IPF management and disease
awareness
Nevertheless, more work is still needed to improve the
diagnosis and management of IPF. In this study, most
patients reported a delayed diagnosis and this is not
uncommon for IPF and other rare diseases [46], as dem-
onstrated by the results of the BLF’s recent survey where
many patients with IPF in England reported struggling to
obtain a diagnosis [22]. Patients in the BLF survey also
reported not having access to information about IPF that
they could understand, having to navigate their own care
pathway, and a lack of access to an ILD specialist nurse.
We should, therefore, continue to seek each patient’s
perspective on their disease and treatment, so that the
information and care they receive can be tailored to their
specific needs, thereby providing the support they and
their families require to live with IPF.
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